N-苯甲酰基-2-(2-羟乙基)哌啶 | 66120-20-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-苯甲酰基-2-(2-羟乙基)哌啶
• 英文名称: N-benzoyl-2-(2-hydroxyethyl)piperidine
• 英文别名: 1-benzoyl-2-piperidineethanol；2-(1-benzoyl-piperidin-2-yl)-ethanol；N-benzoyl-2-piperidineethanol；N-Benzoylpiperidin-2-ethanol；[2-(2-hydroxyethyl)piperidin-1-yl]-phenylmethanone
• CAS: 66120-20-5
• 化学式: C₁₄H₁₉NO₂
• mdl: MFCD03550909
• 分子量: 233.31
• InChiKey: UVJGCTBDCLWLQR-UHFFFAOYSA-N

物化性质

• 沸点：
  397.9±15.0 °C(Predicted)
• 密度：
  1.113±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-苯甲酰基-2-(2-羟乙基)哌啶 、 甲基磺酰氯 、 三乙胺 生成 2-(1-benzoylpiperidin-2-yl)ethyl methanesulfonate
  参考文献：
  名称：

  VEDEJS E.; ARCO M. J.; POWELL D. W.; RENGA J. M.; SINGER S. P., J. ORG. CHEM., 1978, 43, NO 25, 4831-4837

  摘要：

  DOI：
• 作为产物：
  描述：

  2-哌啶乙醇 、 5-benzoyl-3-(cyclopent-1-en-1-yl)-5-phenyl-1,5-dihydro-4H-pyrazol-4-one 以 二氯甲烷 为溶剂， 反应 12.0h， 以95%的产率得到N-苯甲酰基-2-(2-羟乙基)哌啶
  参考文献：
  名称：

  5-酰基-5-苯基-1,5-二氢-4 H-吡唑-4-酮对多胺和氨基糖苷的高度选择性酰化

  摘要：

  可从芳基炔丙基苯基重氮乙酸酯获得的5-酰基-5-苯基-1，5-二氢-4 H-吡唑-4-酮是对二胺和多胺以及氨基醇和氨基硫醇的高度选择性的酰基转移试剂。作为具有碳基离去基团的试剂，它们已用于苯甲酰转移，可广泛选择包含脂肪族氨基与其他竞争性亲核官能团的底物。直接苯甲酰基转移的底物范围和选择性水平超过了已知的苯甲酰化试剂的范围和水平。这些新试剂对与伯碳和仲碳键合的伯胺之间的酰化反应具有出色的选择性，已被用于氨基糖苷类抗生素的直接位点选择性单苯甲酰化。

  DOI：

  10.1039/c7sc03184j

文献信息

• Imidazole 5-position substituted angiotensin II antagonists
  申请人：The Du Pont Merck Pharmaceutical Company

  公开号：US05395844A1

  公开（公告）日：1995-03-07

  Novel substituted imidazoles of Formula (III), which are useful as angiotensin-II antagonists, are disclosed: ##STR1## These compounds, exemplified by the compound 1-((2'-((i-Amyloxycarbonylamino)sulfonyl)-3-fluoro-(1,1'-biphenyl)-4-yl)me thyl)-5-[2-(N-butyryl-N-pyridin-3-ylamino) ethylcarbonyl]-4-ethyl-2-propyl-1H-imidazole, are useful as antihypertensive agents.

  Formula (III)的新型取代咪唑，可用作抗肾素II拮抗剂，已被披露：##STR1## 这些化合物，例如化合物1-((2'-((i-氨氧羰基氨基)磺酰基)-3-氟-(1,1'-联苯)-4-基)甲基)-5-[2-(N-丁酰-N-吡啶-3-基氨基)乙酰基]-4-乙基-2-丙基-1H-咪唑，可用作降压药物。
• Novel piperidine .sigma. receptor ligands as potential antipsychotic drugs
  作者：Paul J. Gilligan、Gary A. Cain、Thomas E. Christos、Leonard Cook、Spencer Drummond、Alexander L. Johnson、Ahmed A. Kergaye、John F. McElroy、Kenneth W. Rohrbach

  DOI：10.1021/jm00101a012

  日期：1992.11

  Sigma receptor ligands represent a new class of potential antipsychotic drugs. This paper presents the structure-activity relationships leading to novel disubstituted piperidine sigma ligands, which have little or no affinity for dopamine D2 receptors. Selectivity for sigma sites over dopamine D2 or serotonin 5-HT2 receptors appears to be governed by the chemical nature of the piperidine nitrogen substituent, its distance from the basic nitrogen, and its orientation relative to the other piperidine substituent. Several of these compounds have good oral potency in some animal models used to evaluate potential antipsychotic drugs. The N-cyclopropylmethyl ketones and ethers (e.g. 6i (DuP 734), 6q, 18a, and 18n) have the best in vivo potency. Compounds 6i (DuP 734) and 6q did not cause catalepsy in the rat, even at very high doses. On the basis of the pharmacology profiles of these sigma ligands, we propose these compounds may be effective antipsychotic drugs, which do not induce extrapyramidal side effects or tardive dyskinesia.
• Microwave-Promoted Transformations:  Fast and Chemoselective N-Acylation of Amino Alcohols Using Catalytic Amounts of Dibutyltin Oxide. Influence of the Power Output and the Nature of the Acylating Agent on the Selectivity
  作者：Anabel Morcuende、Marta Ors、Serafín Valverde、Bernardo Herradón

  DOI：10.1021/jo9605511

  日期：1996.1.1

  The influence of the nature of the acylating agent and the power output on the chemoselectivity of the microwave-mediated acylation of 1,2- and 1,3-amino alcohols catalyzed by dibutyltin oxide has been studied. The method constitutes an efficient procedure for the selective N-acylation of amino alcohols.
• IMIDAZOLE 5-POSITION SUBSTITUTED ANGIOTENSIN II ANTAGONISTS
  申请人：THE DU PONT MERCK PHARMACEUTICAL COMPANY

  公开号：EP0711162A1

  公开（公告）日：1996-05-15
• EP0711162A4
  申请人：——

  公开号：EP0711162A4

  公开（公告）日：1996-09-04